DDX3X Links NLRP11 to the Regulation of Type I Interferon Responses and NLRP3 Inflammasome Activation

Ioannis Kienes1, Sarah Bauer1, Clarissa Gottschild1, Nora Mirza1, Jens Pfannstiel2, Martina Schröder3† and Thomas A. Kufer1*†

1 Department of Immunology, Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany, 2 Core Facility University of Hohenheim, Mass Spectrometry Module, University of Hohenheim, Stuttgart, Germany, 3 Kathleen Lonsdale Institute for Human Health Research, Department of Biology, Maynooth University, Maynooth, Ireland

INTRODUCTION

In mammals, viral infections are detected by anti-viral pattern-recognition receptors (PRRs), including RIG-I-like receptors (RLRs), cytosolic DNA receptors, and endosomal Toll-like receptors (TLRs). Their activation induces antiviral cytokine responses dominated by release of type I interferons (IFNs), which are crucial for limiting replication of most viruses (1–4). Hence, failure to initiate an effective IFN response correlates with higher pathogenicity in many viral infections (5–7). Thus, robust early IFN induction is crucial for controlling viral replication,
but failure to resolve this response can result in severe immunopathology in the host (8–10). In particular an altered balance between type I IFN responses and pro-inflammatory cytokine release can lead to pathology in the host, as seen for example in COVID-19 disease (11, 12). It is therefore critical to understand how type I IFN and pro-inflammatory cytokine responses are balanced during viral infections.

RLRs, most prominently RIG-I, are essential sensors for cytosolic viral RNA (13). Following the binding of viral RNAs, RIG-I oligomerizes and binds to the mitochondrial antiviral signaling protein (MAVS) via CARD-CARD interactions (14). MAVS then recruits downstream signaling proteins, such as TNF-associated factor 2 (TRAF2) (15), TRAF6 (16), and TRAF3 (17), which ultimately lead to induction of pro-inflammatory cytokines and type I IFNs. IFN induction is dependent on phosphorylation of the transcription factors interferon regulatory factor 3 (IRF3) and IRF7 (18–21) mediated by two related kinases, inhibitor of NF-kB kinase subunit epsilon (IKKe) and TANK binding kinase 1 (TBK1) (22, 23). TBK1 is necessary for IFN-β induction and ubiquitously expressed in different cell types, while IKKe may not be essential for IFN-β induction and has been suggested to directly regulate a subset of interferon-stimulated genes (ISGs) (24).

NOD-like receptors (NLRs) are another important group of PRRs and a total of 22 human NLR proteins have been discovered (25), many of which remain to be functionally characterized. NLRs consist of an N-terminal effector domain, a central NACHT domain, and a C-terminal leucine-rich repeat region (LRRs), and can be subcategorized by their effector domains into pyrin-domain (PYD) containing NLRP proteins, CARD-domain containing NLRC proteins, baculovirus inhibitor of apoptosis (BIR)-domain containing NLRB proteins, and CARD-transcriptional activation-domain (CARD-AD) containing NLRA proteins (26).

Signaling pathways induced by NLRs are heterogeneous. While NOD1 and NOD2 induce NF-kB activation upon recognition of bacterial ligands (27–29), NLRP1, NLRP3 and NLR4 activation leads to formation of a large multiprotein signaling platform called the inflammasome (30–32). Inflammasome formation starts with recruitment of the adaptor protein apoptosis-associated speck-like protein (ASC), which then recruits and activates pro-caspase-1, enabling maturation and release of IL-1β and IL-18. Other NLR proteins including NLRP6, NLRP7, NLRP12, and possibly NLRC5 might also form inflammasomes (33–36). However, not all mammalian NLR proteins act as PRRs. For example, NLRC5 and CIITA are transcriptional enhancers for MHC class I and class II genes, respectively (37, 38), and some NLRs have been identified as negative regulators of innate immune responses. An example is NLRC3 that negatively regulates DNA sensing-PRRs by interfering with the adaptor molecule stimulator of interferon genes (STING) (39). Furthermore, NLRP4 (40–42), NLRP12 (43, 44) and NLRP14 (45), were reported to modulate IFN responses (for an overview see (46)).

We and others have previously shown that NLRP11 can negatively regulate both NF-kB activation (47) and type I IFN induction (48, 49). It was shown that NLRP11 interferes with the MAVS signaling complex (47, 49), but it can also block type I IFN induction downstream of TBK1 (48), suggesting that NLRP11 might intervene at multiple levels in the RLR pathway.

A well-established positive regulator of the RLR-pathway is the human DEAD-box protein 3 (DDX3X). DDX3X physically interacts with MAVS (50), IKKε (51), TBK1 (52), TRAF3 (53) and IRF3 (54), resulting in enhanced type I IFN production (50, 51, 53, 54). DDX3X might also be directly involved in recognition of viral RNA (50). Activation of the RIG-I pathway triggers binding of DDX3X to IKKe, which leads to enhanced IKKe activation (51, 54) and IKKe-mediated phosphorylation of DDX3X in its N-terminal region, which enables recruitment of IRF3 into the complex, resulting in enhanced activation of IRF3 by IKKe phosphorylation (54). TBK1 can also phosphorylate DDX3X and enhance IFNβ production (52). The physiological importance of DDX3X’s role in anti-viral immune signaling is underlined by the fact that several viruses, including Vaccinia virus, Hepatitis B virus and Influenza A virus, evolved immune evasion mechanisms targeting DDX3X (51, 55–59). Thus DDX3X is a central regulator of the RIG-I anti-viral signaling pathway, where it interacts with signaling intermediates in a complex manner that is still not completely understood.

Recently, a further role for DDX3X as a positive regulator of NLRP3 inflammasome activation was reported. Sequestration of DDX3X into cytosolic stress granules during cellular stress results in reduced NLRP3/caspase-1 activation and suppression of IL-1β and IL-18 release (60).

A better understanding of the complex molecular circuits that control innate immune responses will advance our understanding of host-pathogen interactions and help to identify novel targets for therapeutic intervention. Here we provide evidence that NLRP11, via its leucine-rich repeats (LRRs), interacts with DDX3X. This interaction inhibited IKKe-induced phosphorylation of DDX3X and type I IFN induction. Using caspase-1 activation assays and ASC speck formation assays, we revealed that NLRP11 can also counteract the positive effect of DDX3X on NLRP3 inflammasome activation. Taken together, our work identified DDX3X as a novel target of NLRP11 that contributes to the inhibitory effects on both type I IFN induction and IL-1β release.

MATERIALS AND METHODS

Plasmids and Reagents

Myc-NLRP11 and myc-NLRP11 domain constructs were previously described (48). The plasmids pcDNA5/FRT/TO-NLRP11-eGFP and pEGFP-DDX3X were generated by molecular cloning from myc-NLRP11 or myc-DDX3X respectively. The Myc-DDX3X construct is described in (51). piGLuc caspase-1 reporter plasmid, pC1-caspase-1 and pCI-ASC-HA were kindly provided by Veit Hornung and are described in (61, 62). FLAG-IKKε was kindly provided by Eliane Meurs (63). Myc-DDX3X mutants were previously...
described in (54). All plasmids (inserts, tags and flanking regions) were verified by Sanger sequencing.

Cell Culture
HEK293T cells (ATCC, CRL-3216) were grown in DMEM supplemented with 10% heat-inactivated FBS. HEK Blue IFN-α/β (hkb-α/hlb, InvivoGen) were maintained in DMEM, supplemented with 10% heat-inactivated FBS, 30 µg/ml basicidin and 100 µg/ml zeocin. THP1 cells with a doxycycline inducible shRNA targeting DDX3X and non-silencing controls (NSC) are described in (64). Cells were grown in RPMI 1640 supplemented with 10% heat-inactivated FBS, gentamycin and puromycin. Knock-down of DDX3X was induced by 1 µg/ml doxycycline for 48 h.

Stable, inducible cell lines expressing NLRP11-eGFP were generated by co-transfection of pOG44 and pcDNA5/FRT/TO-NLRP11-eGFP at 9:1 ratio into Flp-In T-REx HEK293 (Invitrogen/ThermoFischer, R78007) and HeLa FlpIn T-REx cells (kindly provided by the Hentze Lab, EMBL Heidelberg) using Lipofectamine 2000 (Thermo Fisher Scientific) and selected with 10 µg/ml basicidin and either 100 µg/ml (HEK) or 600 µg/ml (HeLa) hygromycin. Single clones were selected, and expression was induced by 1 µg/ml doxycycline for at least 16 h prior to further experiments. All cell culture media were supplemented with penicillin and streptomycin. Cells were routinely monitored for absence of mycoplasma infection by PCR.

For viral infection, cells were incubated with 160 hemagglutination units (HAU)/ml Sendai virus (Cantell Strain in allantoic fluid, Charles River).

siRNA- and shRNA Mediated Silencing
THP1 and THP1shDDX3X cells were differentiated with 100 nM PMA for 16 h. Medium was changed and cells were incubated for 24 h prior to siRNA-mediated knock-down with 100 nM siRNA, transfected using HiPerFect transfection reagent (Qiagen) according to (65). AllStars negative control siRNA and siNLRP11_6 CACGGACTTGCAAGCTGTGAA (48) (Qiagen) were used. Knock-down of NLRP11 was performed for 72 h. For double knock-down of NLRP11 and DDX3X, 24 h after transfection of the siRNA, THP1 shDDX3X cells were induced with 1 µg/ml doxycycline for 48 h.

Knock-down efficiency of NLRP11 was monitored with endpoint PCR as described in (48). Knock-down of DDX3X was monitored by end-point PCR using the following primer pair: fwd: TGCTGGGCTAGACCTGAACT rev: TTGATCCACTTCCAGATCA.

Co-Immunoprecipitation and Protein Binding Assays
Co-immunoprecipitation of NLRP11-eGFP, from HEK293 and HeLa FlpIn eGFP and NLRP11-eGFP cell lines, or of eGFP-DDX3X from HEK293T cells, transiently transfected with Lipofectamine 2000 (Thermo Fisher Scientific), was performed with GFP-Trap Agarose resin (Chromotek). Cells were lysed in Triton buffer [50 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% Triton-X100, 1% Na-Deoxycholate, 100 nM β-glycerophosphate, 100 nM sodium orthovanadate, 1 mM NaF and Complete Mini Protease inhibitor Cocktail (Roche)]. Lysates were cleared by centrifugation (15 min, 4°C, 21000 x g) before the supernatants were loaded onto the matrix. Precipitation was performed at 4°C for 3 h, before the matrix was washed with washing buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% Na-Deoxycholate).

NanolC-MS/MS Analysis
Proteins were digested on beads using trypsin (Roche, Germany) in 6 M urea, 50 mM Tris-HCl pH 8.5. Cysteines were reduced using 1,4-dithiothreitol (DTT) and then alkylated by chloroacetamide. Samples were then diluted to a final concentration of 2 M urea. 750 ng trypsin were added, and samples were digested overnight at 25°C. The digests were stopped by adding trifluoroacetic acid (TFA). Next, peptide mixtures were concentrated and desalted on C18 stage tips and dried under vacuum. Samples were dissolved in 0.1% TFA and subjected to nanoLC-MS/MS analysis on an EASY-nLC 1000 system (Thermo Fisher Scientific, Germany) coupled to a Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific, Germany) using an EASY-Spray nanoelectrospray ion source (Thermo Fisher Scientific, Germany). The system was controlled by Xcalibur 3.0.63 software. Tryptic peptides were directly injected to a 25 cm x 75 µm EASY-Spray analytical column (2 µm, 100 Å, PepMap C18) operated at 35°C. Peptides were separated at a flow rate of 250 nl/min using a 120 min gradient with the following profile: 3% - 10% solvent B in 50 min, 10% - 22% solvent B in 40 min, 22% - 45% solvent B in 30 min, 45% - 90% solvent B in 10 min, 15 min isocratic at 90% solvent B, followed by 90% - 3% solvent B in 10 min and re-equilibration at 3% solvent B for 15 min. (solvent A: 0.5% acetic acid; solvent B: acetonitrile/H₂O (80/20, v/v), 0.5% acetic acid).

MS spectra (m/z = 300-1600) were detected at a resolution of 70000 (m/z = 200) using a maximum injection time (MIT) of 100 ms and an automatic gain control (AGC) value of 1 × 10⁶. MS/MS spectra were generated for the 10 most abundant peptide precursors using high energy collision dissociation (HCD) fragmentation at a resolution of 17500, normalized collision energy of 27 and an intensity threshold of 1.3 × 10⁵. Only ions with charge states from +2 to +5 were selected for fragmentation using an isolation width of 1.6 Da. For each MS/MS scan, the AGC was set at 5 × 10⁵ and the MIT was 100 ms. Mascot 2.6 (Matrix Science, UK) was used as search engine for protein identification. Spectra were searched against the human UniProt database (66). Scaffold 4.8.6. (Proteome Software, USA) was used to evaluate peptide identifications. These were accepted with a peptide probability greater than 80% as specified by the Peptide Prophet algorithm (67). Proteins had to be identified by at least one unique peptide and a protein probability of at least 99% to be accepted.

Reporter Assays
For iGLuc caspase-1 reporter assays, HEK293T cells were seeded in a 96-well plate (Greiner) at a density of 35,000 cells per well and transiently transfected using Xtreme Gene 9 transfection reagent (Sigma Aldrich) with 8.6 ng β-galactosidase plasmid, 42 ng of the iGLuc reporter plasmid (61), and expression plasmids of NLRP3, NLRP11, ASC, caspase-1 and DDX3X,
DDX3X S102A, or DDX3X 4A as indicated. 20 h after transfection, cells were stimulated with 15 μM nigericin (InvivoGen) for 3 h. Cells were then lysed in 100 μl passive lysis buffer (Promega) per well. 50 μl of the cell lysate were transferred into a non-transparent 96-well plate. Luciferase activity was measured in a multimeter reader (Eppendorf, PerkinElmer LifeSciences) after addition of 100 μl of 3.33 μM Coelenterazine (Carl Roth) per well. 100 μl of 1 mg/ml O-nitrophenyl-β-D-galactopyranoside in 60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl and 1 mM MgSO4 were added to the remaining 50 μl lysate, incubated at 37°C and absorption was measured at 405 nm (620 nm reference) as β-galactosidase activity. Luciferase activity was normalized to β-galactosidase activity.

Ifnβ luciferase reporter assays were performed as described in (48), with 5 ng FLAG-IKKε plasmid for activation.

Assays were performed in technical triplicates and repeated independently three times unless indicated otherwise.

Indirect Immunofluorescence
HeLa FlpIn cells were seeded into 24-well plates at a density of 75,000 cells per well on glass coverslips, HEK FlpIn cells at 100,000 cells per well on poly-L-lysine pretreated glass coverslips and expression of eGFP or eGFP-NLRP11 was induced with 1 µg/ml doxycycline. After overnight expression, cells were either infected with 160 hemagglutination units (HAU)/ml Sendai virus (SeV) for different durations, or directly fixed with 4% PFA in PBS, permeabilized with 0.5% Triton X-100 and blocked with 5% FBS in PBS. Cells were then incubated with primary and secondary antibody sequentially. Antibodies used: Primary: DDX3X (A300-474A Bethesda Laboratories), AIF (Cell Signalling # 4642). Secondary: Alexa-546 goat anti-rabbit IgG, Alexa-405 goat anti-mouse (Molecular Probes). DNA was stained with Hoechst 33258 (Sigma). Images were captured with a Leica DMi8 microscope using a HCX PL FL L 40X/0.60 or a HC PL APO 63X/1.40-0.60 OIL objective and processed using the Leica LasX software and ImageJ. For 3D deconvolution, Z-stacks of 4.05 μm depth were captured, with individual planes every 0.2 μm. Blind 3D-deconvolution was performed using the Leica LasX software, performing 10 iterations at a refractive index of 1.52. For quantitative analysis, sample pictures were blinded and counted by eye.

Immunoblotting
Immunoblotting was performed as described in (65). Antibodies used: β-actin (C-4; Santa Cruz sc-7778), GFP (Roche 11 814 460 001), myc (9E10; Sigma Aldrich M4439), DDX3X (Bethyl Laboratories A300-474A), FLAG (Sigma Aldrich F7425), GAPDH (Santa Cruz sc-25778), pIFR3 (Cell Signalling #29047T).

Measurement of Cytokines
IL-1β and IFNβ release was measured in cell supernatants by ELISA (DY201, DY814, R&D Systems) according to the manufacturer’s instructions. A bioassay for type I interferons was performed using HEK Blue IFN-α/β cells (Invivogen). HEK Blue IFN-α/β cells were stimulated for 20 h with supernatant from SeV infected THP1 cells and SEAP activity in the supernatant was measured by Quantiblue solution (rep-qbs, InvivoGen) according to the manufacturer’s conditions.

Statistical Analysis
Data were analyzed by unequal variances t-test (Welch test) and plotted using GraphPad Prism version 7.05. p < 0.05 was regarded as significant.

RESULTS
NLRP11 Interacts With the ATP-Dependent RNA Helicase DDX3X
We recently demonstrated that NLRP11 is a negative regulator of inflammatory cytokine induction (48). In order to study the underlying molecular mechanism, we generated an eGFP-tagged NLRP11 (NLRP11-eGFP) expression construct and confirmed that NLRP11-eGFP retained its negative regulatory effect on IKKε induced ifnβ-reporter gene expression in comparison to our previously used myc-NLRP11 construct (Figure 1A). Stable cell lines allowing for inducible expression of NLRP11-eGFP were generated using the doxycycline inducible single site recombination system Flp-In T-REx. We obtained stable HeLa and HEK293 lines that showed inducible expression of NLRP11-eGFP after doxycycline treatment, as well as control cell lines expressing eGFP only. We selected for cell lines with tight regulation, uniform expression in all cells, and well detectable expression upon induction (Figure 1B). We noticed that NLRP11-eGFP tended to form high molecular weight SDS-stable aggregates in both HEK293 and HeLa cells (Figure 1B, upper band), which we also observed for myc-NLRP11 (data not shown). However, we always also detected monomeric NLRP11 in SDS-PAGE, and fluorescent microscopy also confirmed that NLRP11-eGFP was distributed in the cytoplasm without formation of larger aggregates, consistent with earlier reports (48, 49). Nonetheless, we noticed that NLRP11 was not completely evenly distributed in the cytosol, suggesting it might associate with cellular organelles (Figure 1C).

Next, we used these stable cell lines to identify interaction partners of NLRP11. NLRP11-eGFP protein complexes were immunoprecipitated from the HeLa-NLRP11-eGFP cells using anti-GFP antibody. Co-immunoprecipitated proteins were identified by mass spectrometry. We obtained several putative NLRP11 interactors that were not detected in two independent control immunoprecipitation experiments conducted with the corresponding eGFP-expressing HeLa cell line (Supplementary Table 1). Due to its well-described functions in anti-viral innate immune signaling (51, 52, 68), we selected the DEAD-box protein DDX3X as the most interesting candidate for further analysis. To validate the interaction, we used a specific antibody directed against DDX3X. In independent experiments we could confirm the presence of endogenous DDX3X in co-immunoprecipitations from HEK293-NLRP11-eGFP cells, while it was absent in co-immunoprecipitations conducted with HEK293-eGFP control cells (Figure 1D). Unfortunately, due to lack of a specific antibody against human NLRP11, we could not assess the interaction with endogenous NLRP11.
To map the interaction domain for DDX3X in NLRP11, we expressed myc-tagged NLRP11 truncation mutants in HEK293T cells together with eGFP-DDX3X or empty vector and performed immunoprecipitations using anti-GFP antibody. We also confirmed binding of myc-NLRP11 to DDX3X in these experiments (Figure 1E). Deletion of the NLRP11 PYD did not influence binding, nor was the PYD sufficient to facilitate binding to DDX3X. While the LRR domain alone showed a strong interaction with DDX3X, we only observed limited binding of the NACHT domain to DDX3X (Figure 1E). This finding is in line with results obtained in our previous work, where we showed that the LRR domain of NLRP11 is sufficient for inhibition of TBK1-induced type I IFN (48).

Next we set out to analyze the functional relevance of the DDX3X-NLRP11 interaction. First, we tested whether the NLRP11-DDX3X complex formation changed during Sendai virus (SeV) infection. Starting at 4 h post infection, we observed increased expression levels and co-immunoprecipitation of endogenous DDX3X with NLRP11-eGFP in HEK293 cells that was strongest at 6 h and 16 h post infection (Figure 2A).

We next analyzed the subcellular localization dynamics of NLRP11 and DDX3X during infection with SeV by indirect immunofluorescence microscopy. In HEK293-NLRP11-eGFP cells we confirmed co-localization of NLRP11 and DDX3X in the cytosol. This co-localization was maintained and appeared slightly enhanced during SeV infection with more pronounced co-localization at 16 h post infection compared to steady state levels (Figure 2B). Co-localization of DDX3X and NLRP11-eGFP was also observed in HeLa-NLRP11-eGFP cells, where NLRP11-eGFP continued to stably co-localize with DDX3X over the course of 16 h of infection in the majority of cells (Figure 2C). However, NLRP11 was not recruited to distinct DDX3X clusters that appeared at 16 h post infection in a minority of cells (Figure 2D). The formation of these structures was also not influenced by the presence, or absence of NLRP11-eGFP (Figure 2D). These structures likely represent stress granules that DDX3X is known to be recruited into (60, 69, 70) and were only present in a minority of the cells. In line with data previously published by Qin et al. (49), HEK293-NLRP11-eGFP cells showed no co-localization of NLRP11-eGFP with the mitochondrial marker apoptosis-inducing factor (AIF) at steady state conditions, but we observed recruitment of NLRP11 to mitochondria at 16 h post infection (Figure 2E). In HeLa NLRP11-eGFP cells, NLRP11 was localized in proximity to mitochondria in untreated cells and this localization pattern persisted during 16 h of SeV infection, with partial co-localization observed at 16 h post infection (Figure 2F).

Taken together, we identified DDX3X as a novel binding partner of NLRP11. Mapping of the interaction domain in NLRP11 identified that the LRR region was sufficient for DDX3X binding. We further demonstrated that the interaction
between NLRP11 and DDX3X occurred in the cytosol in proximity to mitochondria.

**NLRP11 Prevents the Post-Translational Modification of DDX3X by IKKe**

Gu et al. reported that IKKe can phosphorylate DDX3X and that this is a prerequisite for the interaction of DDX3X with IRF3 and subsequent activation of the Ifnb promoter (54). We therefore investigated whether NLRP11 influences this posttranslational modification of DDX3X. As shown before, co-expression of IKKe and DDX3X in HEK293T cells induced a change in the electrophoretic mobility of DDX3X, which is indicative of phosphorylation (54). This up-shift of DDX3X was clearly suppressed by co-expression of NLRP11 (Figure 3A).

We have previously shown that the ability of NLRP11 to inhibit TBK1-induced IFNβ production is dependent on its LRRs (48). Given that the LRR region also interacted with DDX3 (Figure 1E), we tested whether this domain is required and
sufficient to inhibit IKKe-mediated DDX3X phosphorylation and, consequently, downstream activation of IRF3 (54). Expression of full–length NLRP11, NLRP11-ΔPYD and NLRP11-LRR reduced the IKKe-induced upshift of DDX3X, while this was not observed for the PYD or NACHT domain of NLRP11. Consistent with this data, activation of IRF3, assessed by serine 396 phosphorylation, was also strongly reduced when NLRP11 full length, ΔPYD or the LRRs were expressed (Figure 3B).

Next, in order to interrogate the consequences of the DDX3X-NLRP11 interaction on IFNβ induction, we performed siRNA-mediated knock-down of NLRP11 in macrophage-like differentiated human THP1 cells in which DDX3X expression can be suppressed by Tet-inducible expression of a specific short hairpin RNA (shRNA) (THP1 shDDX3X) (64). THP1 cells were used for these experiments because they express higher levels of endogenous NLRP11 and IKKe compared to HeLa and HEK293T cells (48). In accordance with recent data (48, 49), knock-down of NLRP11 led to significantly increased IFNβ production in response to SeV infection (Figure 3C). As reported previously (51), shRNA-mediated knock-down of DDX3X had the opposite effect and reduced SeV-induced IFNβ expression (Figure 3C). However, DDX3X depletion resulted in a similar ratio of IFNβ reduction compared to control (−Dox) in both siCtrl cells and siNLRP11 treated cells (Figure 3C). Qualitatively similar results were obtained when measuring IFNβ activity in a bioassay (Figure 3C).

Overall, our data suggest that NLRP11 represses type I interferon responses by affecting IKKe-mediated posttranslational modification of DDX3X.

**NLRP11 Counteracts the Effect of DDX3X on NLRP3 Inflammasome Activation**

Considering the recent identification of DDX3X as a positive regulator of NLRP3 inflammasome formation (60), we next investigated whether NLRP11 affects DDX3X’s function in this context. We previously showed that NLRP11 cannot induce caspase-1 activation itself, nor does NLRP11 recruit the inflammasome adaptor ASC (48), suggesting that NLRP11 does not form a classical inflammasome when ectopically expressed in cells. Instead, we observed a trend towards reduced caspase-1 activation when NLRP11 was overexpressed (48). We therefore now investigated whether NLRP11 interferes with NLRP3 inflammasome activation, conceivably via sequestration of DDX3X. In line with the report from the Kanneganti lab (60), DDX3X enhanced nigericin-induced...
pro-caspase-1 cleavage, as measured by the iGLuc reporter assay, where a luciferase protein gets activated by caspase-1 cleavage in HEK293T cells (61) (Figure 4A). Expression of increasing amounts of myc-NLRP11 did not significantly affect NLRP3 inflammasome activation in the absence of exogenous DDX3X expression but led to a dose-dependent reduction of caspase-1 activation back to baseline levels in DDX3X overexpressing cells (Figure 4A).

To determine whether the LRRs of NLRP11 were involved in the negative regulation of the NLRP3 inflammasome, we performed caspase-1 activation assays with our different NLRP11 truncation mutants. Expression of full-length NLRP11

![Figure 4A](image-url)

**FIGURE 4** | NLRP11 suppresses NLRP3 inflammasome activation by DDX3X. (A, B) iGLuc caspase-1 reporter assay in HEK293T cells expressing myc-NLRP3 (15 ng), HA-ASC, and caspase-1 (10 ng each) together with the indicated proteins. Cells were treated with 15 µM nigericin for 3 h. Means of three independent experiments (each conducted in triplicates) ± SEM are shown. *p < 0.05; **p < 0.01 Welch’s, two-sided t-test. (B), values relative to the mean of three independent experiments conducted in triplicates of cells, transfected with the reporter plasmid, NLRP3, ASC and caspase-1, not treated with nigericin, are shown. (C) Indirect immunofluorescent micrographs of HeLa-eGFP or HeLa-NLRP11-eGFP cells, induced with doxycycline overnight and transfected with HA-ASC and myc-NLRP3. Staining for HA and myc, as well as eGFP-signal is shown. Images representative of three independent experiments are shown. Scale bar = 50 µm. HA-ASC expressing cells without speck-formation are indicated with white arrow heads. Right panels: Quantification of cells with myc-NLRP3 specks and quantification of cells with HA-ASC staining (blinded counting of 150 cells per condition from n = 3). (D) iGLuc caspase-1 reporter assay in HEK293T cells expressing myc-NLRP3 (15 ng), HA-ASC, and caspase-1 (10 ng each) together with the indicated proteins. Cells were treated with 15 µM nigericin for 3 h. Means of three independent experiments (each conducted in triplicates) ± SEM are shown. (E) IL-1β release from macrophage-like differentiated THP1 cells after 72 h of siRNA-mediated knock-down. Cells were primed for 4 h with 100 ng/ml LPS followed by stimulation with 10 µM nigericin for 2 h. Means of five independent experiments ± SEM are shown. (Inlay: endpoint PCR for NLRP11 and GAPDH of a representative experiment for validation of knock-down efficiency. n.s., not stimulated.)
or the LRRs led to a significant reduction of nigericin-induced caspase-1 activation. The same trend was observed in cells expressing only endogenous DDX3X (Figures 4A, B). NLRP11, NLRP11-ΔPYD and NLRP11-LRRs also caused a significant decrease in baseline caspase-1 activity (in the absence of nigericin) both in the presence and absence of exogenous DDX3X (Figure 4B). Taken together, this data shows that the LRRs of NLRP11 are both necessary and sufficient to dampen NLRP3 inflammasome activation, which might be a result of DDX3X recruitment and sequestration via the LRR domain of NLRP11. To provide further evidence we performed ASC speck-formation assays. When we co-expressed HA-ASC together with myc-NLRP3 in our HeLa cell lines, we found fewer ASC specks in NLRP11-eGFP-expressing cells compared to eGFP-expressing cells that served as control. Quantitative analysis revealed a reduction from about 51% speck-containing cells for HeLa-eGFP cells to about 31% for HeLa-NLRP11-eGFP cells (Figure 4C). Equal transfection efficiency of both cell lines was confirmed by blinded counting of HA-ASC positive cells (Figure 4C). This data strongly suggests that NLRP11 can inhibit assembly of NLRP3 inflammasomes.

In Figures 3A, B, we showed that NLRP11 suppresses IKKe-mediated phosphorylation of DDX3X. We next asked whether this phosphorylation plays a role in the regulation of NLRP3 inflammasome activation by DDX3X. To this end, we performed iGlc reporter assays with the S102A mutant of DDX3X lacking the IKKe-phosphorylation site shown to be critical for IRF3 recruitment to DDX3X and IFNβ induction. We also tested another DDX3X mutant in which three further IKKe-phosphorylation sites in the N-terminus of DDX3X (S71A, S82A, S83A) are mutated in addition to S102 (54). We did not observe any differences in the capacity of these DDX3X mutants to enhance caspase-1 activation both in presence and absence of NLRP11 expression (Figure 4D), suggesting that these DDX3 phosphorylation events do not regulate its effect on inflammasome formation.

Finally, to corroborate a negative regulatory role for NLRP11 in inflammasome induced caspase-1 activation, we knocked down endogenous NLRP11 expression in macrophage-like differentiated THP1 cells using a specific siRNA (48). We first primed the differentiated THP1 cells with LPS and then induced NLRP3 inflammasome activation with nigericin. IL-1β secretion, a well-established read-out for NLRP3 inflammasome activation, was measured. Knock-down of NLRP11 resulted in increased IL-1β secretion (Figure 4E), albeit this effect was not significant (p=0.1086).

Taken together, these data provide evidence that NLRP11 can negatively regulate NLRP3 inflammasome activation and suggest that this is mediated via its interaction with DDX3X.

DISCUSSION

Tight control and coordinated resolution of pro-inflammatory signaling pathways is an essential part of the immune response. While insufficient activation of innate immunity might provide pathogens the opportunity to thrive, an overshooting immune response can result in immunopathology. Many control mechanisms have therefore evolved that meticulously regulate the activation level of innate immune responses. We and others previously showed that NLRP11 can act as a negative regulator of antiviral type I IFN expression (48, 49) and NF-κB-dependent pro-inflammatory cytokine responses (47). Here we expand the mechanistical understanding of NLRP11’s regulation of antiviral responses by showing that it interacts with and inhibits the DEAD-box protein DDX3X (Figure 5). DDX3X has previously been shown to enhance the RIG-I-mediated antiviral response at multiple levels (50–54). Interestingly, other DEAD-box helicases have also been shown to form complexes with NLR family members: In mice, Nlrp9b uses the DEAD-box protein Ddx9 as a sensor for double-stranded RNA to induce inflammasome activation and pyroptosis following infection with dsRNA viruses (71). Ddx15 has also been shown to sense viral RNA and to bind to Nlrp6, mediating its interaction with MAVS (72). Sensing of viral and bacterial RNA by DHX33 has been shown to induce an interaction with NLRP3, enhancing inflammasome formation and caspase-1 activation (73). The latter interaction was shown to be dependent on the NACHT domain of NLRP3. Similarly, the DDX3X interaction with NLRP3 was also mediated by the NACHT domain, resulting in enhanced activation of caspase-1 (60). In contrast, we demonstrated that the interaction between NLRP11 and DDX3X is mediated by the LRRs of NLRP11. This difference in binding domains might explain why some interactions between DExD/H-box proteins and NLR proteins result in increased activation of immune signaling pathways, whereas the interaction we describe here has a negative regulatory effect. The LRR domain of NLRP11 has already been shown to inhibit type I IFN induction upon viral challenge (48, 49). Here we show that the LRR domain is also sufficient to inhibit hyperphosphorylation of DDX3X induced by IKKe (51, 54). This supports our hypothesis that NLRP11’s repression of IFN induction is at least partially mediated by targeting DDX3X.

DDX3X is known to positively regulate the RIG-I pathway by interacting with multiple downstream signaling molecules. RIG-I signals via its mitochondrial adaptor protein MAVS to induce type I IFN transcription (50). Previously, NLRP11 was shown to be recruited to MAVS via its LRRs to modulate TRAF6 function and stability (49). However, no direct physical interaction between NLRP11 and MAVS was shown in this study. This raises the possibility that DDX3X could be involved in mediating this NLRP11-MAVS interaction. In our HEK293-NLRP11-eGFP cell line, we confirmed recruitment of NLRP11 to mitochondria 16 h post infection, as visualized by co-staining with AIF, however, the cellular morphology was heavily disturbed after 16 h of virus infection. The physiological relevance of the change in subcellular localization of NLRP11 in this cell type thus remains elusive.

Surprisingly, NLRP11 knock-down still increased IFNβ induction in DDX3X knock-down cells (Figures 3C, D). However, our DDX3X knock-down was only partial as
DDX3X is required for cell viability, and therefore residual DDX3X protein levels might have affected the outcome of this experiment. It is also possible, that the NLRP11-DDX3X interaction more strongly perturbs the function of IKKe in ISG induction (74, 75) than IFNβ induction which is more TBK1-mediated (23, 76). This would explain why NLRP11 interferes with antiviral signaling at multiple steps downstream of RIG-I, enabling it to negatively regulate expression of both IFN (47–49) and ISGs that are directly regulated by IKKe.

In addition to this role in regulating antiviral gene expression, we provide evidence that NLRP11 can act as a negative regulator of the NLRP3 inflammasome. We confirmed that DDX3X is a positive regulator of the NLRP3 inflammasome, as reported recently (60) and show that expression of NLRP11 counteracts this effect of DDX3X. We also observed a trend towards higher IL-1β secretion upon NLRP11 knock-down in macrophage-like differentiated THP1 cells, but the rather low NLRP11 expression levels in THP1 cells (48) might limit the effect of siRNA-mediated knock-down.

The PYD domain of NLRP11 was not required for blocking the DDX3X effect on the NLRP3 inflammasome, instead expression of the NLRP11 LRRs was sufficient. Samir et al. proposed that recruitment of DDX3X by NLRP3 is critical for functional inflammasome formation (60). This is in line with our data, which suggests that NLRP11 binding to DDX3X via its LRRs reduces caspase-1 activation. It would be interesting whether this effect results from DDX3X sequestration by NLRP11 or competition between NLRP3 and NLRP11 for binding sites on DDX3X. When overexpressing NLRP11-eGFP in HeLa cells, we did not observe an obvious change in the subcellular localization of endogenous DDX3X, arguing against the sequestration mechanism. Another possibility is that NLRP11 inhibits posttranslational modifications of DDX3X that are important for its involvement in the NLRP3 inflammasome. This hypothesis is based on our finding that the NLRP11 LRRs inhibited the NLRP3 inflammasome and prevented IKKe-mediated hyperphosphorylation of DDX3X. Although we were unable to implicate the phosphorylation sites of DDX3X that are involved in IRF3 activation (54) in its regulatory effect on the NLRP3 inflammasome, it is likely that other DDX3X post-translational modifications could also be affected by NLRP11.

In summary, we show that NLRP11 is an NLR family member that negatively regulates NLRP3 inflammasome activity and interferes with the induction of antiviral type I IFN. For both regulatory effects, we identified a novel role for DDX3X, which we discovered as a novel binding partner of NLRP11, putting a further spotlight on this interesting DEAD-box protein.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

IK, SB, and CG performed the experiments and analyzed data. JP performed MS analysis and data interpretation. MS provided reagents. NM provided essential conceptional input and edited
the manuscript. IK, MS, and TK wrote and edited the manuscript and figures. MS and TK conceptualized the study, analyzed data, and assured funding. All authors contributed to the article and approved the submitted version.

FUNDING
IK acknowledges support by the Landesgraduiertenförderung of Baden-Württemberg. Research in the MS laboratory was funded by Science Foundation Ireland and the Irish Health Research Board.

REFERENCES

1. Daffa S, Samuel MA, Keller BC, Gale MJr., Diamond MS. Cell-Specific IRF-3 Responses Protect Against West Nile Virus Infection by Interferon-Dependent and -Independent Mechanisms. PLoS Pathog (2007) 3(7):e106. doi: 10.1371/journal.ppat.0030106

2. Chopdy D, Dettje CN, Lafage M, Kaltanke U, Lafon M. The Type I Interferon Response Bridges Rabies Virus Infection and Reduces Pathogenicity. J Neurovirol (2011) 17(4):353–67. doi: 10.1007/s13365-011-0041-6

3. Dettje CN, Meyer T, Schmidt H, Kreuz D, Rose JK, Bechmann I, et al. Local Type I IFN Receptor Signaling Protects Against Virus Spread Within the Central Nervous System. J Immunol (2009) 182(4):2297–304. doi: 10.4049/jimmunol.0800596

4. Schilte C, Couderc T, Chretien F, Soursseau M, Gangneux N, Guivel-Benhassine F, et al. Type I IFN Controls Chikungunya Virus Via its Action on Nonhematopoietic Cells. J Exp Med (2010) 207(2):429–42. doi: 10.1084/jem.20090851

5. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe (2016) 19(2):181–93. doi: 10.1016/j.chom.2016.01.007

6. Shepardson KM, Larson K, Johns LL, Stanek K, Cho H, Wellham J, et al. IFnar2 Is Required for Anti-influenza Immunity and Alters Susceptibility to Post-influenza Bacterial Superinfections. Front Immunol (2018) 9:2589. doi: 10.3389/fimmu.2018.02589

7. Sandler NG, Bosingier SE, Estes JD, Zhu RT, Tharp GK, Bertiz E, et al. Type I Interferon Responses in Rhesus Macaques Prevent SIV Infection and Slow Disease Progression. Nature (2014) 511(7511):601–5. doi: 10.1038/nature13554

8. Channappanavar R, Fehr AR, Zheng I, Wehlford-Leraine C, Abrahante J, Mack M, et al. IFN-γ Response Relative to Virus Replication Determines MERS Coronavirus Infection Outcomes. J Clin Invest (2019) 129(9):3625–39. doi: 10.1172/jci126363

9. Rotger M, Dalmaj N, Rauch A, McLaren P, Bosingier SE, Martinez R, et al. Comparative Transcriptomics of Extreme Phenotypes of Human HIV-1 Infection and SIV Infection in Sooty Mangabey and Rhesus Macaque. J Clin Invest (2011) 121(6):2391–400. doi: 10.1172/jci45235

10. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, Dumoutier L, et al. Alpha and Lambda Interferon Together Mediate Suppression of CD4 T Cells Induced by Respiratory Syncytial Virus. J Virol (2006) 80(10):5032–40. doi: 10.1128/jvi.013354

11. Acharya D, Liu G, Gack MU. Dysregulation of Type I Interferon Responses in COVID-19. Nat Rev Immuno (2020) 20(7):397–8. doi: 10.1038/s41577-020-0346-x

12. Jamilloux Y, Henry T, Belot A, Viel S, Fautier M, El Jammal T, et al. Should We Stimulate or Suppress Immune Responses in COVID-19? Cytokine and Anti-Cytokine Interventions. Autoimmun Rev (2020) 19(7):102567. doi: 10.1016/j.autrev.2020.102567

13. Rehwinkel J, Gack MU. Rig-1-like Receptors: Their Regulation and Roles in RNA Sensing. Nat Rev Immuno (2020) 20(9):537–51. doi: 10.1038/s41577-020-0288-3

14. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS Forms Functional Prion-Like Aggregates to Activate and Propagate Antiviral Innate Immune Response. Cell (2011) 146(3):484–61. doi: 10.1016/j.cell.2011.06.041

15. Lad SP, Yang G, Scott DA, Chao TH, Correia Jda S, de la Torre JC, et al. Identification of MAVS Splicing Variants That Endure With RIG1/MAVS Pathway Signaling. Mol Immunol (2008) 45(8):2277–87. doi: 10.1016/j.molimm.2007.11.018

16. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu BH. VISA is an Adapter Protein Required for Virus-Triggered IFN-beta Signaling. Mol Cell (2005) 19(6):727–40. doi: 10.1016/j.molec.2005.08.014

17. Saha SK, Pietras EM, He JQ, Kang JR, Liu SY, Oganessyan G, et al. Regulation of Antiviral Responses by a Direct and Specific Interaction Between TRAF3 and Cardil. EMBO J (2006) 25(14):3257–63. doi: 10.1038/sj.emboj.7601220

18. Au WC, Moore PA, Lowther W, Juang YT, Pithe PM. Identification of a Member of the Interferon Regulatory Factor Family That Binds to the Interferon-Stimulated Response Element and Activates Expression of Interferon-Induced Genes. Proc Natl Acad Sci USA (1995) 92(25):11657–61. doi: 10.1073/pnas.92.25.11657

19. Juang YT, Lowther W, Kellum M, Au WC, Lin R, Hiscott J, et al. Primary Activation of Interferon A and Interferon B Gene Transcription by Interferon Regulatory Factor 3. Proc Natl Acad Sci USA (1995) 92(17):9837–42. doi: 10.1073/pnas.92.17.9837

20. Lin R, Heybroeck C, Pithe PM, Hiscott J. Virus-Dependent Phosphorylation of the IRF-3 Transcription Factor Regulates Nuclear Translocation, Transactivation Potential, and Proteasome-Mediated Degradation. Mol Cell Biol (1998) 18(5):2986–96. doi: 10.1128/mcb.18.5.2986

21. Au WC, Moore PA, LaFleur DW, Tombal B, Pitha PM. Characterization of the Interferon Regulatory Factor-7 and its Potential Role in the Transcription Activation of Interferon A Genes. J Biol Chem (1998) 273(44):29210–7. doi: 10.1074/jbc.273.44.29210

22. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. Ikkepsilon and TBK1 are Essential Components of the IRF3 Signaling Pathway. Immunity, Cell Death, and Diseases. Mol Immunol (2003) 39:491–6. doi: 10.1016/sj.immuno.2002.01.123

23. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, et al. The Nod2 is a General Sensor of Peptidoglycan Through Muramyl Dipeptide and Activates NF-kappaB and MAPKs in Diverse Cell Types. Cell (1998) 92(25):11657–61. doi: 10.1074/jbc.273(44):29210–7. doi: 10.1074/jbc.273.44.29210

24. Liebisch G, Klaiber M, Hiscott J, Pithe PM. The Nod2 is a General Sensor of Peptidoglycan Through Muramyl Dipeptide. Mol Immunol (2003) 39:63. doi: 10.1016/sj.immuno.2003.01.026

25. Liwinski T, Zheng D, Elinav E. The Microbiome and Cytosolic Innate Immune Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. J Virol (2006) 80(10):5032–40. doi: 10.1128/jvi.013354

26. Nod2 is a General Sensor of Peptidoglycan Through Muramyl Dipeptide. Mol Immunol (2003) 39:63. doi: 10.1016/sj.immuno.2003.01.026

ACKNOWLEDGMENTS
We thank Yvonne Postma for technical assistance with experiments and Camille Vasilin for help with cloning and the characterization of the NLRP11 constructs.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.653883/full#supplementary-material
Kienes et al. NLRP11 Regulates DDX3X

(MDP) Detection. J Biol Chem (2003) 278(11):8869–72. doi: 10.1074/jbc.M200585120

39. Ikeda N, Kosuki T, del Peso L, Hu Y, Zee C, Chen S, et al. Nod1, an Apaf-1-like Activator of Caspase-9 and Nuclear Factor-KappaB. J Biol Chem (1999) 274(1):14560–7. doi: 10.1074/jbc.274.1.14560

40. Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES. The Nlrp12 Regulates MHC Class II Transactivator Mutated in Hereditary MHC Class II Deficiency. J Immunol (2011) 186(1):313–7. doi: 10.1073/pnas.1008684107

41. Gu L, Fullam A, McCormack N, Höhn Y, Schröder M. DDX3X Directly Regulates TRAF3 Ubiquitination and Acts as a Scaffold to Co-Ordinate Assembly of Signalling Complexes Downstream From MAVS. Biochem J (2017) 474(4):571–87. doi: 10.1042/bj20160956

42. Gu L, Fullam A, Brennan R, Schröder M. Human DEAD Box Helicase 3 Couples Ikb Kinase e to Interferon Regulatory Factor 3 Activation. Mol Cell (2013) 51(3):363–76. doi: 10.1016/j.molcel.2012.11.012

43. Zhao L, Mo J, Swanson KV, Wen H, Petrucelli A, Gregory SM, et al. NLRCA, a Member of the NLR Family of Proteins, is a Negative Regulator of Innate Immune Signaling Induced by the DNA Sensor STING. EMBO J (2012) 31(3):463–76. doi: 10.1038/emboj.2012.002

44. Neerincx A, Lautz K, Menning M, Kremmer E, Zigrino P, Hösel M, et al. A DEAD-box Helicase DDX3X is a Critical Component of the TANK-binding Kinase 1-Dependent Innate Immune Response. EMBO J (2008) 27(5):1315–46. doi: 10.1038/emboj.2008.126

45. Oda S, Schröder M, Khan AR, et al. Poxvirus K7 Protein Adopts a Bcl-2 Fold: Biochemical Mapping of its Interactions With Human DEAD Box RNA Helicase DDX3. J Biol Mol (2009) 385(3):843–53. doi: 10.1016/j.jmb.2008.09.048

46. Liu, Fullam A, McCormack N, Höhn Y, Schröder M. DDX3X Directly Regulates TRAF3 Ubiquitination and Acts as a Scaffold to Co-Ordinate Assembly of Signalling Complexes Downstream From MAVS. Biochem J (2017) 474(4):571–87. doi: 10.1042/bj20160956

47. Wang L, Manji GA, Grenier JM, Al-Garawi A, Merriam S, Lora JM, et al. The NLRP3-Containing Inflammasome Mediated by the IFAP/ NLRCA Inflammasome. J Exp Med (2007) 204(13):3235–45. doi: 10.1084/jem.20071239

48. Ellwanger K, Becker E, Kienes I, Sowa A, Postma Y, Cardona Gloria Y, et al. The NLR Family Pyrin Domain-Containing 11 Protein Contributes to the Regulation of Inflammatory Signaling. J Biol Chem (2018) 293(8):2701–10. doi: 10.1074/jbc.RA117.000152

49. Qin Y, Su Z, Wu Y, Wu C, Jin S, Xie W, et al. NLRP11 Disrupts MAVS Signalosome to Inhibit Type I Interferon Signaling and Virus-Induced Apoptosis. EMBO Rep (2017) 18(12):1761–70. doi: 10.15252/embj.201744480

50. Oshimi H, Sakai K, Matsumoto M, Seya T, Dead/BOX 3 (DDX3X) Helicase Binds the RIG-I Adaptor IIPS-1 to Up-Regulate IFN-beta-inducing Potential. Eur J Immunol (2010) 40(4):940–8. doi: 10.1002/eji.200940203

51. Schroder M, Baran M, Bowie AG. Viral Targeting of DEAD Box Protein 3 Reveals its Role in TBK1/IKKepsilon-mediated IRF Activation. EMBO J (2008) 27(15):2147–57. doi: 10.1038/emboj2008.143

52. Kalverda AP, Thompson GS, Vogel A, Schröder M, Bowie AG, Khan AR, et al. Poxxviruses Use the K7 Protein Adopts a Bcl-2 Fold: Biochemical Mapping of its Interactions With Human DEAD Box RNA Helicase DDX3. J Biol Mol (2009) 385(3):843–53. doi: 10.1016/j.jmb.2008.09.048

53. Steinle V, Otten LA, Zufferey M, Mach B. Complementation Cloning of an Activating Adaptor for Caspase-1. J Biol Chem (2002) 277(24):2119–22. doi: 10.1074/jbc.C201792000

54. Martinez-Torres RJ, Chauvin C, Normand S, Waldschmitt N, Neerincx A, Martinez-Torres RJ, Chauvin C, et al. PYPAF7, a Novel PYRIN-containing Apaf1-like Protein That Regulates Mitochondrial DNA Release. J Biol Chem (2010) 285(21):16956–68. doi: 10.1074/jbc.M109.989975

55. Kalverda AP, Thompson GS, Vogel A, Köster M, Bowie AG, Khan AR, et al. Poxxvirus K7 Protein Adopts a Bcl-2 Fold: Biochemical Mapping of its Interactions With Human DEAD Box RNA Helicase DDX3. J Biol Mol (2009) 385(3):843–53. doi: 10.1016/j.jmb.2008.09.048

56. Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES. The Nlrp12 Regulates MHC Class II Transactivator Mutated in Hereditary MHC Class II Deficiency. J Immunol (2011) 186(1):313–7. doi: 10.1073/pnas.1008684107

57. Wang L, Manji GA, Grenier JM, Al-Garawi A, Merriam S, Lora JM, et al. NLRCA, a Member of the NLR Family of Proteins, is a Negative Regulator of Innate Immune Signaling Induced by the DNA Sensor STING. Immunity (2014) 40(3):329–41. doi: 10.1016/j.immuni.2014.01.010

58. Cai J, Li Y, Zhu L, Liu D, Songyang Z, Wang HY, et al. NLRP4 Negatively Regulates Type I Interferon Signaling by Targeting the Kinase TBK1 for Degradation Via the Ubiquitin Ligase DTX4. Nat Immunol (2012) 13(4):387–95. doi: 10.1038/ni.2239

59. Davis BK, Roberts RA, Huang MT, Willingham SB, Conti BJ, Brickey WJ, et al. Cutting Edge: NLRC5-dependent Activation of the Inflammasome. J Immunol (2011) 186(6):1333–7. doi: 10.4049/jimmunol.1003111

60. Chen ST, Chen L, Lin DS, Chen SY, Tsao YP, Guo H, et al. Nlrp12 Regulates MHC Class II Transactivator Mutated in Hereditary MHC Class II Deficiency. J Immunol (2011) 186(1):313–7. doi: 10.1073/pnas.1008684107

61. Caffrey DR, et al. AIM2 Recognizes Cytosolic dsDNA and Forms a caspase-1-activating Inflammation. Nature (2009) 46(4):387–95. doi: 10.1038/nature08725

62. Horning V, Ablaster A, Charrell-Dennis M, Bauenfeld F, Horvath G, Caffrey DR, et al. ADM2 Recognizes Cytosolic dsDNA and Forms a caspase-1-activating Inflammation With ASC. Nature (2009) 458(7237):514–8. doi: 10.1038/nature07725

63. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the Interferon Antiviral Response Through an IKBK-related Pathway. Science (2003) 300(5622):1148–51. doi: 10.1126/science.1081315

64. Neerincx A, Lautz K, Menning M, Kremmer E, Zigrino P, Hösel M, et al. A DEAD-box Helicase DDX3X is a Critical Component of the TANK-binding Kinase 1-Dependent Innate Immune Response. EMBO J (2008) 27(5):1315–46. doi: 10.1038/emboj.2008.126

65. Neerincx A, Lautz K, Menning M, Kremmer E, Zigrino P, Hösel M, et al. A Role for the Human Nucleotide-Binding Domain, Leucine-Rich Repeat-Containing Family Member NLRCA in Antiviral Responses. J Biol Chem (2010) 285(34):26223–32. doi: 10.1074/jbc.M110.99736

66. UniProt Consortium. UniProt: The Universal Protein Knowledgebase. Nucleic Acids Res (2018) 46(5):2699. doi: 10.1093/nar/gky092
67. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical Statistical Model to Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database Search. Anal Chem (2002) 74(20):5383–92. doi: 10.1021/ac025747h
68. Szapponos D, Tschismarov R, Perlot T, Westermayer S, Fischer K, Platanitis E, et al. The RNA Helicase DDX3X is an Essential Mediator of Innate Antimicrobial Immunity. PLoS Pathog (2018) 14(11):e1007397. doi: 10.1371/journal.ppat.1007397
69. Pene V, Li Q, Sodroski C, Hsu CS, Liang Tj. Dynamic Interaction of Stress Granules, DDX3X, and IKK-alpha Mediates Multiple Functions in Hepatitis C Virus Infection. J Virol (2015) 89(10):5462–77. doi: 10.1128/JVI.03197-14
70. Shih JW, Wang WT, Tsai TY, Kuo CY, Li HK, Wu Lee YH. Critical Roles of RNA Helicase DDX3 and its Interactions With eIF4E/PABP1 in Stress Granule Assembly and Stress Response. Biochem J (2012) 441(1):119–29. doi: 10.1042/Bj201110739
71. Zhu S, Ding S, Wang P, Wei Z, Pan W, Palm NW, et al. Nlrp9b Inflammasome Restricts Rotavirus Infection in Intestinal Epithelial Cells. Nature (2017) 546(7660):667–70. doi: 10.1038/nature22967
72. Wang P, Zhu S, Yang L, Cui S, Pan W, Jackson R, et al. Nlrp6 Regulates Intestinal Antiviral Innate Immunity. Science (2015) 350(6262):826–30. doi: 10.1126/science.aab3145
73. Mitoma H, Hanabuchi S, Kim T, Bao M, Zhang Z, Sugimoto N, et al. The DHX33 RNA Helicase Senses Cytoplasmic RNA and Activates the NLRP3 Inflammasome. Immunity (2013) 39(1):123–35. doi: 10.1016/j.immuni.2013.07.001
74. Matsui K, Kumagai Y, Kato H, Sato S, Kawagoe T, Uematsu S, et al. Cutting Edge: Role of TANK-binding Kinase 1 and Inducible IkappaB Kinase in IFN Responses Against Viruses in Innate Immune Cells. J Immunol (2006) 177(9):5785–9. doi: 10.4049/jimmunol.177.9.5785
75. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T. Multiple Functions of the IKK-related Kinase IKKepsilon in Interferon-Mediated Antiviral Immunity. Science (2007) 315(5816):1274–8. doi: 10.1126/science.1136567
76. Perry AK, Chow EK, Goodnough JB, Yeh WC, Cheng G. Differential Requirement for TANK-binding Kinase-1 in Type I Interferon Responses to Toll-Like Receptor Activation and Viral Infection. J Exp Med (2004) 199(12):1651–8. doi: 10.1084/jem.20040528

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Kienes, Bauer, Gottschild, Mirza, Pfannstiel, Schröder and Kufer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.